echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > WuXi Junuo Announces Its Cellular Immunotherapy Drug Has Successfully Benefited 200 Chinese Patients

    WuXi Junuo Announces Its Cellular Immunotherapy Drug Has Successfully Benefited 200 Chinese Patients

    • Last Update: 2022-05-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>



    As the first product of WuXi Junuo, a class 1 new drug CAR-T product , Benoda® (Ruiji Orenza Injection), achieved the first patient reinfusion treatment in December 2017, and it will also be the first patient in 2022.


    WuXi Junuo has successfully built a world-leading cellular immunotherapy technology and product development platform, as well as a product pipeline covering blood and solid tumors, and has carried out 9 clinical studies on blood and solid tumors


    About Benoda® ( Rigiorenza Injection)

    Benoda® (Ruiji Orenza Injection) is a CD19-targeting drug independently developed by WuXi Junuo on the basis of the CAR-T cell technology platform of Junuo Medical (a company of Bristol-Myers Squibb).


    About WuXi Junuo

    WuXi Junuo (HKEx: 2126) is an independent, innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products


    Forward-Looking Statements

    The forward-looking statements contained in this release are based on management's existing expectations and beliefs and are subject to certain uncertainties or risks that could cause actual results to differ materially from those described


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.